Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response

27 Jun 2023

An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.

Natural killer cells — Nkarta reported mixed data for its NK cell therapy in AML • Source: Shutterstock

More than a year after reporting promising early data for its allogeneic chimeric antigen receptor natural killer (CAR-NK) candidate NKX101 in relapsed/refractory acute myeloid leukemia, Nkarta, Inc. disappointed investors on 27 June with an update several analysts called underwhelming, but also provided some hope with data from six AML patients who received a different chemotherapy conditioning regimen prior to the cell therapy.

The South San Francisco-based firm’s stock finished the trading day down substantially, falling 38% to $2.81 per share, but Nkarta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

10 Jun 2025

• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

10 Jun 2025

• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

10 Jun 2025

• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.